|
Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma, Clinical Trials Info presented on Clinical Trials Search is not intended to be a substitute for certified medical advice, visits or professional assistance using a real physician. We are not physicians. Always consult your dr. about Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma, conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma, Clinical research trials and Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma, health trials happen in many of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new drugs. The function of the studies / projects is to resolve particular human medical questions. Clinical trials are a popular manner for mDs, government agencies, and private sector corporations to discover remedies for all varieties of circumstances, like Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma,. Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma, Clinical Trials and other clinical trials allow volunteers to obtain healthcare treatment options before they are available to the masses. Some times the participants undergo professional assistance for free of charge, and occasionally they are paid for their time. Sometimes there is a cost for a Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma, clinical trial. Human subjects often get the best healthcare available for their Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma, condition. Dangers are a reality, however, and may include additional or frequent mD visits, healthcare dangers (potentially life-jeopardising), and/or the treatment being ineffectual. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma,  Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma,
Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma,
For Condition: Non-Hodgkins Lymphoma,Hodgkins Disease
Status: Recruiting
Sponsor(s): Baylor College of Medicine , Texas Children's Hospital,The Methodist Hospital
Synopsis: Some patients with Hodgkin or non-Hodgkin Lymphoma show evidence of infection with the virus that causes infectious mononucleosis Epstein Barr virus (EBV) before or at the time of their diagnosis of Lymphoma. EBV is often found in the cancer cells suggesting that it may play a role in causing Lymphoma. The cancer cells infected by EBV are very clever because they are able to hide from the body's immune system and escape destruction. We want to see if we can grow special white blood cells, called T cells, that have been trained to kill EBV infected cells and then give them back to the patient. To find out how long these cells last we may put a marker gene into them so we can track them. Gene marking is optional in this study. Eligible patients can participate without the gene marking if they choose. The purpose of this study is to find the largest safe dose of EBV specific cytotoxic T cells, to learn what the side effects are and to see whether this therapy might help patients with Hodgkin disease and non-Hodgkins Lymphoma.
Details: We will take 60-70 ml (12 teaspoonfuls) of blood from the patient to make a B cell line called a lymphoblastoid cell line or LCL by infecting the blood with a laboratory strain of EBV called B95. We will then use this EBV infected cell line (which have been treated with radiation so that they cannot grow) as stimulator cells and mix it with more blood. This stimulation will train the T cells to kill EBV infected cells and result in the growth of an EBV specific T cell line. We will then test the T cells to make sure that they kill the EBV infected cells and not normal cells and freeze them. Patients will be entered into one of three different dosing schedules being evaluated. Three to six patients will be evaluated on each dosing schedule. Escalation will continue until irreversible or life threatening side effects considered to be related to the T cells are seen. For patients who agree to gene marking (this is optional), we will mark these cells with a special bacterial marker gene. We will use a mouse virus (retrovirus) that has been changed to stop it from causing infection. The marker, a gene called Neo, is put inside this special virus. The cells will be injected into the patients' vein over 10 minutes, after pretreatment with Tylenol and Benadryl. Tylenol and Benadryl are given to prevent a possible allergic reaction to the T cell administration. A total of two doses will be given two weeks apart. All of the treatments will be given at Texas Children's Hospital or The Methodist Hospital. Patients will be followed in the clinic after the injections. At each visit about 10ml (2 teaspoonfuls) of blood will be taken every other week for 6 weeks after the injection and then every 3 months for 1 year to monitor the patients' blood chemistry and hematology. For patients who agreed to gene marking, an extra 8 teaspoons (40 mls) of blood will be taken before each infusion, 24 hours after each infusion, 3-4 days after each infusion and at 1, 2, 4, and 6 weeks post infusion and then at 3, 6, 9 and 12 months post infusion) then once every 6 months for the first 5 years and then yearly thereafter for the next 10 years. We will use this blood to test for the frequency and activity of EBV specific T cells. That is, to learn more about the way the T cells are working and how long they last in the body. We will also use this blood to see if there are any long term side effects of gene transfer. Patients who received cells that have a marker gene will need to be followed (seen in clinic or contacted by a research nurse) at least every six months for the next five years and then yearly thereafter for the next ten years so we can see if there are any long term side effects of the gene transfer.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Any patient with EBV positive Hodgkin disease or non-Hodgkin Lymphoma, in second relapse regardless of age or sex, in first relapse or with primary disease or in first remission if immunosuppressive chemotherapy is contraindicated, e.g. patients who develop Hodgkin disease after solid organ transplantation or if the Lymphoma is a second malignancy e.g. a Richters transformation of CLL. - Patients with a life expectancy >6 weeks. - Patients with a Karnofsky score of > 50. - No severe intercurrent infection. - Patient, parent/guardian able to give informed consent. - Patients with bilirubin <2x normal, SGOT <3x normal, and Hgb >8.0. - Patients with a creatinine <2x normal for age or creatinine clearance >2x normal for age. - Patients should have been off other investigational therapy for one month prior to entry in this study. Exclusion Criteria - Patients with an EBV positive NHL secondary to an acquired or congenital immunodeficiency. - Patients with a life expectancy of <6 weeks. - Patients with a Karnofsky score of < 50. - Patients with a severe intercurrent infection. - Patient, parent/guardian unable to give informed consent. - Patients with a bilirubin >2x normal. SGOT >3x normal or abnormal prothrombin time. - Patients with a creatinine >2x normal for age or creatinine clearance <2x normal for age. - Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom.
Total Enrollment: 18
Location and Contact Information:
The Methodist Hospital *Recruiting*
Houston, Texas, 77030
United States
Recruiting Helen Heslop 832-824-4662
Texas Children's Hospital *Recruiting*
Houston, Texas, 77030
United States
Recruiting Helen Heslop 832-824-4662
Additional Information:
Study ID Numbers: 6423; Angel
Study Start Date: January 1996
Record last reviewed: December 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00058617
Other Hodgkins Disease Studies:
1. Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma,
Related Studies:
Other Hodgkins Disease Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Giving Gene Marked(Optional) Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells to Patients with Relapsed EBV-Positive Lymphoma,
|
|
|
|
|
|
|
|
